Topic:

Infectious Diseases

Latest Headlines

Latest Headlines

Novavax reports positive top-line data from PhII trial of RSV vaccine

There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.

State vaccination laws impact outbreak rates, study finds

A University of Georgia study found that lax state vaccination laws lead to lower immunization rates and increased outbreaks of preventable diseases. The authors--David Bradford and Anne Mandich--also noted that exemption rates have dramatically risen in the last 10 years, attributable to religious and philosophical reasons.

Merck Ebola vaccine posts 100% efficacy in PhIII

Merck's Ebola vaccine, developed in tandem with NewLink, has protected 100% of patients from Ebola infection, according to interim results published in The Lancet on Friday.

Pfizer's U.S. Prevnar 13 sales jump 87% in Q2

The world's biggest vaccine by sales--Prevnar 13--just keeps getting bigger. And in doing so, the shot helped Pfizer notch 44% vaccines growth for the second quarter as the unit saw sales grow from $1.09 billion in last year's Q2 to $1.58 billion during the period this year.

Glaxo's malaria vaccine gets EMA green light

GlaxoSmithKline's malaria vaccine, RTS,S or Mosquirix, has won a positive opinion from the EMA's Committee for Medicinal Products for Human Use for use in children aged 6 weeks to 17 months outside the European Union, the agency said in a statement.

SutroVax bags $22M Series A to develop vaccines for infectious diseases

SutroVax, the vaccine spinoff from Fierce 15 honoree Sutro Biopharma that is developing vaccines for infectious diseases, announced Thursday the completion of a $22 million Series A financing.

Sanofi's dengue vaccine anticipated on profitability 'high end'

With its largest ever investment in a vaccine at stake, Sanofi is in the midst of rolling out the dengue fever vaccine it's worked on for 20 years at a cost of $1.5 billion. But through the launch, Sanofi hopes to recoup all of that expense--plus more.

Reuters: WHO, EMA likely to approve GlaxoSmithKline's malaria vaccine despite challenges

Final trial results reported in April showed that the efficacy of GlaxoSmithKline's investigational malaria vaccine wanes over time. But the candidate, dubbed RTS,S or Mosquirix, is the furthest along in the quest for a vaccine and so, may win WHO and EMA approval as the first vaccine against malaria.

GSK and J&J/Bavarian Nordic take Ebola candidates to Senegal, Europe

Although the waning Ebola outbreak had Big Pharmas struggling to find volunteers for their Ebola vaccine trials, two new Phase II trials are going forward. GlaxoSmithKline will take its candidate to Senegal, while Johnson & Johnson and partner Bavarian Nordic will test their vaccine in France and the U.K.

NIAID launches PhI trial of investigational West Nile virus vaccine

The mosquito-borne West Nile virus has infected more than 41,000 people and killed more than 1,700 people in the U.S. since 1999. But while there is an effective veterinary vaccine for the virus, there is no commercially available human vaccine. The National Institutes of Health's NIAID is launching a Phase I trial of a human vaccine at Duke University.